Luvox CR Related Published Studies
Well-designed clinical trials related to Luvox CR (Fluvoxamine)
Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. [2010.07]
Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. [2009.05]
Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents. [2009.04]
Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia. [2008.12]
[Additional treatment in chronic pain syndrome due to hip and knee arthritis with the selective serotonin reuptake inhibitor fluvoxamine (Fevarin] [2008.11]
Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. [2007.04]
Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. [2006.08]
Effects of caffeine on the kinetics of fluvoxamine and its major metabolite in plasma after a single oral dose of the drug. [2006.06]
[A double-blind controlled study of the efficacy and acceptability of tianeptine in comparison with fluvoxamine in the treatment of depressed alcoholic patients] [2006.05]
Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. [2006.05]
Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. [2006.04]
Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. [2006.03]
Blindness of clinical evaluators, parents, and children in a placebo-controlled trial of fluvoxamine. [2006.02]
[Comparison of the effectiveness of two treatment strategies in inpatients with a depressive disorder. A double-blind study of imipramine followed by lithium addition versus fluvoxamine followed by lithium addition] [2006]
Fluvoxamine affects sildenafil kinetics and dynamics. [2005.12]
Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. [2005.11]
Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. [2005.11]
Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. [2005.10]
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. [2005.07]
Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. [2005.06]
Interaction study between enoxacin and fluvoxamine. [2005.06]
Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial. [2005.05]
The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. [2005.05]
Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. [2005.05]
Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial. [2005.04]
Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oophorectomized women with hot flashes and depressive tendencies. [2005.04]
Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. [2005.01]
A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression. [2005.01]
Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. [2005.01]
A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine. [2005]
Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder. [2004.11]
Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. [2004.11]
Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia. [2004.08]
Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. [2004.07.13]
Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. [2004.06]
Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. [2004.04]
A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. [2004.02]
Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition. [2004]
Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. [2003.12]
A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. [2003.06]
Well-designed clinical trials possibly related to Luvox CR (Fluvoxamine)
SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents. [2011.02]
Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled
randomized trials. [2011]
Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression. [2010.06]
Influence of gender and menopausal status on antidepressant treatment response in depressed inpatients. [2010.04]
Prevalence of trait anxiety in a sample of depressed inpatients and its influence on response to antidepressants. [2010.04]
Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules. [2010.03.04]
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. [2010.03]
No effect of adding brief dynamic therapy to pharmacotherapy in the treatment of obsessive-compulsive disorder with concurrent major depression. [2010]
Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a
systematic review of placebo-controlled studies. [2010]
Remission with mirtazapine and selective serotonin reuptake inhibitors: a
meta-analysis of individual patient data from 15 controlled trials of acute phase
treatment of major depression. [2010]
Effectiveness of medications used to attenuate antipsychotic-related weight gain
and metabolic abnormalities: a systematic review and meta-analysis. [2010]
Are typical starting doses of the selective serotonin reuptake inhibitors
sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled,
dose-finding studies in major depressive disorder. [2010]
Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive
disorder. [2010]
A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. [2009.06]
Pharmacological REM sleep suppression paradoxically improves rather than impairs skill memory. [2009.04]
Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. [2008.10]
Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers. [2008.05]
In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. [2008]
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. [2007.07.13]
Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. [2007.04]
Effectiveness of a meditation-based stress management program as an adjunct to pharmacotherapy in patients with anxiety disorder. [2007.02]
Sleep-related problems among children and adolescents with anxiety disorders. [2007.02]
The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. [2007.01]
Phenytoin as an augmentation for SSRI failures: a small controlled study. [2006.11]
Somatic symptoms in children and adolescents with anxiety disorders. [2006.10]
Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve. [2006.10]
Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve. [2006.06]
Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder. [2006.05]
Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. [2005.10.01]
Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder. [2005.09]
Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed? [2005.09]
Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. [2005.08.15]
Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. [2005.05]
A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. [2005.03]
[Duration effect on neuropsychological function and treatment response of OCD] [2005]
Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. [2004.12]
The advantages of choosing antiobsessive therapy according to decision-making functioning. [2004.12]
Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. [2004.11]
Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. [2004.08.15]
[Estimation of therapeutical efficacy of weak variable magnetic fields with low value of induction in patients with depression] [2004.03]
Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. [2004.01]
Selective serotonin reuptake inhibitors for migraine prophylaxis. [1999.01]
Other research related to Luvox CR (Fluvoxamine)
Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. [2010.12]
Differences in clinical effect and tolerance between fluvoxamine and paroxetine: a switching study in patients with depression. [2010.11]
Sigma1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice. [2010.11]
Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions. [2010.10]
Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. [2010.06]
[Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods] [2010.04]
Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. [2010.04]
Fluvoxamine versus other anti-depressive agents for depression. [2010.03.17]
Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. [2010.03]
Predictors of treatment response to fluvoxamine in obsessive-compulsive disorder: an fMRI study. [2010.03]
Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine. [2010.02]
Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population. [2010]
Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients. [2010]
Extended-release fluvoxamine and improvements in quality of life in patients with
obsessive-compulsive disorder. [2010]
Fluvoxamine versus other anti-depressive agents for depression. [2010]
Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia? [2009.12]
Effective treatment with low-dose fluvoxamine for obsessive-compulsive disorder after neurosurgery: a case report. [2009.11]
[SSRI antidepressants and negative schizophrenic symptoms: differences between paroxetine and fluvoxamine in patients treated with olanzapine] [2009.09]
Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. [2009.08.01]
|
